- Home
- ESPR vs PNNT Comparison
ESPR vs PNNT Comparison
Compare ESPR & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- PNNT
- Stock Information
- Founded
- ESPR 2008
- PNNT 2007
- Country
- ESPR United States
- PNNT United States
- Employees
- ESPR N/A
- PNNT N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- PNNT Finance: Consumer Services
- Sector
- ESPR Health Care
- PNNT Finance
- Exchange
- ESPR Nasdaq
- PNNT Nasdaq
- Market Cap
- ESPR 445.6M
- PNNT 457.1M
- IPO Year
- ESPR 2013
- PNNT 2007
- Fundamental
- Price
- ESPR $2.76
- PNNT $6.89
- Analyst Decision
- ESPR Buy
- PNNT Sell
- Analyst Count
- ESPR 6
- PNNT 4
- Target Price
- ESPR $6.50
- PNNT $6.33
- AVG Volume (30 Days)
- ESPR 6.0M
- PNNT 459.7K
- Earning Date
- ESPR 11-06-2025
- PNNT 08-11-2025
- Dividend Yield
- ESPR N/A
- PNNT 14.07%
- EPS Growth
- ESPR N/A
- PNNT 21.65
- EPS
- ESPR N/A
- PNNT 0.80
- Revenue
- ESPR $268,125,000.00
- PNNT $130,923,000.00
- Revenue This Year
- ESPR $9.87
- PNNT N/A
- Revenue Next Year
- ESPR N/A
- PNNT N/A
- P/E Ratio
- ESPR N/A
- PNNT $8.56
- Revenue Growth
- ESPR N/A
- PNNT N/A
- 52 Week Low
- ESPR $0.69
- PNNT $5.72
- 52 Week High
- ESPR $3.94
- PNNT $7.53
- Technical
- Relative Strength Index (RSI)
- ESPR 71.69
- PNNT 35.11
- Support Level
- ESPR $2.69
- PNNT $6.79
- Resistance Level
- ESPR $2.85
- PNNT $7.29
- Average True Range (ATR)
- ESPR 0.17
- PNNT 0.10
- MACD
- ESPR -0.00
- PNNT -0.04
- Stochastic Oscillator
- ESPR 82.72
- PNNT 20.64
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.